Repligen (NASDAQ:RGEN) Coverage Initiated at TD Cowen

TD Cowen assumed coverage on shares of Repligen (NASDAQ:RGEN - Get Free Report) in a report released on Monday, Marketbeat Ratings reports. The brokerage set a "buy" rating and a $200.00 price target on the biotechnology company's stock. TD Cowen's price objective would suggest a potential upside of 36.83% from the stock's previous close.

Several other equities research analysts also recently issued reports on the stock. Wolfe Research assumed coverage on shares of Repligen in a research note on Thursday, November 14th. They set a "peer perform" rating on the stock. HC Wainwright dropped their target price on Repligen from $240.00 to $180.00 and set a "buy" rating on the stock in a research report on Thursday, January 23rd. Canaccord Genuity Group assumed coverage on Repligen in a report on Tuesday, December 17th. They issued a "hold" rating and a $165.00 price target for the company. Canaccord Genuity Group started coverage on Repligen in a research note on Tuesday, December 17th. They set a "hold" rating and a $165.00 price objective for the company. Finally, StockNews.com raised Repligen from a "sell" rating to a "hold" rating in a research report on Friday, January 3rd. Six investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $186.00.

Repligen Stock Up 0.3 %

Shares of RGEN stock traded up $0.45 during trading hours on Monday, reaching $146.17. The company had a trading volume of 519,443 shares, compared to its average volume of 552,770. The company has a market capitalization of $8.19 billion, a P/E ratio of -395.04, a price-to-earnings-growth ratio of 4.54 and a beta of 0.99. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. Repligen has a twelve month low of $113.50 and a twelve month high of $211.13. The stock's fifty day simple moving average is $155.39 and its 200 day simple moving average is $149.11.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. The company had revenue of $154.87 million during the quarter, compared to the consensus estimate of $153.34 million. During the same quarter last year, the company earned $0.23 earnings per share. Repligen's revenue for the quarter was up 9.7% on a year-over-year basis. As a group, sell-side analysts expect that Repligen will post 1.54 earnings per share for the current fiscal year.

Institutional Trading of Repligen

A number of institutional investors and hedge funds have recently modified their holdings of RGEN. Signaturefd LLC boosted its holdings in shares of Repligen by 172.2% in the 4th quarter. Signaturefd LLC now owns 196 shares of the biotechnology company's stock valued at $28,000 after buying an additional 124 shares during the period. Sava Infond d.o.o. acquired a new position in Repligen in the fourth quarter valued at approximately $29,000. UMB Bank n.a. boosted its stake in Repligen by 138.3% in the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company's stock valued at $33,000 after acquiring an additional 130 shares during the period. Blue Trust Inc. grew its holdings in shares of Repligen by 113.4% during the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 127 shares during the last quarter. Finally, Resources Management Corp CT ADV acquired a new stake in shares of Repligen during the 3rd quarter worth approximately $37,000. 97.64% of the stock is owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.